Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England.

More search options...

Powell, AA; Power, L; Westrop, S; McOwat, K; Campbell, H; Simmons, R; Ramsay, ME; Brown, K; Ladhani, SN; Amirthalingam, G (2021) Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. Euro Surveill, 26 (28). ISSN 1560-7917 https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100634
SGUL Authors: Ladhani, Shamez Nizarali

Preview

PDF Published Version
Available under License Creative Commons Attribution.
Download (239kB) | Preview

Official URL: https://doi.org/10.2807/1560-7917.ES.2021.26.28.21...

Abstract

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5-98.1 vs 48% (41.0-57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5-98.2 vs 75.0% (57.8-87.9).

Item Type:

Article

Additional Information:

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Any supplementary material referenced in the article can be found in the online version. This article is copyright of the authors or their affiliated institutions, 2021.

Keywords: